Although predictions made from these experiments are consistent with in vivo studies of combinations of ispinesib and saracatinib in murine GBM models, it remains possible that local variations in microenvironment from tumor to tumor may alter the efficacy of combined Kif11 and STAT3 targeting. The gene discussed is STAT3; the disease is glioblastoma.